Dr. Jean-Pierre ARMAND (MD, MSc) – Oncologist, Pega2 Scientific Coordinator

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI). He was recently General Director of the Institut Claudius Regaud in Toulouse. After a position as research fellow in Columbia University New York, Dr Armand has joined Institut Claudius Regaud in Toulouse where he was the head of Medical oncology until 1984. In the next 23 years at Institut Gustave Roussy (IGR) in Paris, he was successively CEO of the Hospital IGR3, head of the Department of Medical oncology at IGR2 and CMO of IGR&D, Dept of Innovation and Development. He founded the IGR Phase I Unit (Ditep) in the early 80s.

He conducted the phase 1 trials of numerous drugs now used routinely, including classicals cytotoxics,topo2 inhibitors, Irinotecan, Oxaliplatin, Taxotere, Navelbine, Vinflunine, and more recently targeted therapies, Sutent, Sorafenib, Temsirolimus... His involvement was critical in the success of 3 drugs that had been previously discarded after failure in phase 1 (CPT11 (Irinotecan), Oxaliplatin and SU11248 (Sutent))

Dr Armand started working on early drug development (phase 1 and 2) of new anticancer agents. He is expert in breast, head & neck, and neuro-oncology. He (co)authored over 300 medical and scientific peer-reviewed articles and he is/was member of the Editorial Boards of Annals of Oncology, the European Journal of Cancer, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Research., CISCO journal.

He today focuses on new therapies for orphan treatment cancer diseases and personally invest into biotech in oncology.